非酒精性脂肪性肝炎治疗药物的进展

钱帅杰; 谷劲岳; 高锦航; 童欢

doi:10.3969/j.issn.1001-5256.2020.12.039

非酒精性脂肪性肝炎治疗药物的进展

DOI: 10.3969/j.issn.1001-5256.2020.12.039

1. 四川大学华西临床医学院
2. 四川大学华西医院消化疾病研究室
3. 四川大学华西医院人类疾病相关多肽研究室
4. 四川大学华西医院消化内科

基金项目:

国家自然科学基金青年科学项目（81700539）；四川省科技计划项目（2020YFS0236）；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 563
- HTML全文浏览量: 56
- PDF下载量: 104
- 被引次数: 0
出版历程
- 收稿日期: 2020-05-31
- 出版日期: 2020-12-20

Advances in therapeutic drugs for nonalcoholic steatohepatitis

West China Medical School,Sichuan University
Lab of Gastroenterology and Hepatology,West China Hospital,Sichuan University
Division of Peptides Related Human Disease,West China Hospital,Sichuan University
Department of Gastroenterology,West China Hospital,Sichuan University

Research funding:

摘要

摘要:
非酒精性脂肪性肝炎患病率逐年上升,对有效的治疗药物提出了迫切需求。近年来,相关药物不断涌现,种类繁多,包括:抗氧化应激药物、胰岛素增敏剂、PPAR激动剂、甲状腺受体激动剂、法尼酯X受体激动剂、ASK1抑制剂、全caspase激动剂等。精选关于非酒精性脂肪性肝炎治疗药物的临床研究进行回顾,总结各种药物的疗效及安全性,以期为临床实践提供参考意见。
- 非酒精性脂肪性肝炎 /
- 药物疗法 /
- 随机对照试验(主题)
Abstract:
The incidence rate of nonalcoholic steatohepatitis is gradually increasing year by year,which calls for an urgent need for effective therapeutic drugs. In recent years,various drugs have been developed,including anti-oxidative stress drugs,insulin sensitizers,PPAR agonists,thyroid receptor agonists,farnesoid X receptor agonists,ASK1 inhibitors,and pan-caspase inhibitors. This article reviews the clinical studies on the therapeutic drugs for nonalcoholic steatohepatitis and summarizes the efficacy and safety of each drug,in order to provide a reference for clinical practice.
- non-alcoholic steatohepatitis /
- drug therapy /
- randomized controlled trials as topic

HTML全文

参考文献(30)

[1] YOUNOSSI ZM,OTGONSUREN M,HENRY L,et al. Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to2009[J]. Hepatology,2015,62(6):1723-1730.

[2] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.

[3] YOUNOSSI Z,TACKE F,ARRESE M,et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.

[4] YOUNOSSI Z,HENRY L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality[J]. Gastroenterology,2016,150(8):1778-1785.

[5] ROMERO-GMEZ M,ZELBER-SAGI S,TRENELL M. Treatment of NAFLD with diet,physical activity and exercise[J]. J Hepatol,2017,67(4):829-846.

[6] ALKHOURI N,SCOTT A. An update on the pharmacological treatment of nonalcoholic fatty liver disease:Beyond lifestyle modifications[J]. Clin Liver Dis(Hoboken),2018,11(4):82-86.

[7] LAVINE JE,SCHWIMMER JB,van NATTA ML,et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:The TONIC randomized controlled trial[J]. JAMA,2011,305(16):1659-1668.

[8] SANYAL AJ,CHALASANI N,KOWDLEY KV,et al. Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med,2010,362(18):1675-1685.

[9] BRIL F,BIERNACKI DM,KALAVALAPALLI S,et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2diabetes:A randomized controlled trial[J]. Diabetes Care,2019,42(8):1481-1488.

[10] SHENOY KT,BALAKUMARAN LK,MATHEW P,et al. Metadoxine versus placebo for the treatment of non-alcoholic steatohepatitis:A randomized controlled trial[J]. J Clin Exp Hepatol,2014,4(2):94-100.

[11] MUSSO G,GAMBINO R,CASSADER M,et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease[J]. Hepatology,2010,52(1):79-104.

[12] SINGH S,SINGH PP,SINGH AG,et al. Anti-diabetic medications and the risk of hepatocellular cancer:A systematic review and meta-analysis[J]. Am J Gastroenterol,2013,108(6):881-891; quiz 892.

[13] BELFORT R,HARRISON SA,BROWN K,et al. A placebocontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis[J]. N Engl J Med,2006,355(22):2297-2307.

[14] AITHAL GP,THOMAS JA,KAYE PV,et al. Randomized,placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J]. Gastroenterology,2008,135(4):1176-1184.

[15] RATZIU V,GIRAL P,JACQUEMINET S,et al. Rosiglitazone for nonalcoholic steatohepatitis:One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy(FLIRT)trial[J]. Gastroenterology,2008,135(1):100-110.

[16] ARMSTRONG MJ,GAUNT P,AITHAL GP,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):A multicentre,double-blind,randomised,placebo-controlled phase 2 study[J]. Lancet,2016,387(10019):679-690.

[17] RATZIU V,HARRISON SA,FRANCQUE S,et al. Elafibranor,an agonist of the peroxisome proliferator-activated receptor-αand-δ，induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology,2016,150(5):1147-1159. e5.

[18] NEUSCHWANDER-TETRI BA,LOOMBA R,SANYAL AJ,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):A multicentre,randomised,placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.

[19] PATEL K,HARRISON SA,ELKASHAB M,et al. Cilofexor,a nonsteroidal FXR agonist,in non-cirrhotic patients with nonalcoholic steatohepatitis:A phase 2 randomized controlled trial[J]. Hepatology,2020.[Online ahead of print]

[20] HARRISON SA,BASHIR MR,GUY CD,et al. Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis:A multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J]. Lancet,2019,394(10213):2012-2024.

[21] LOOMBA R,LAWITZ E,MANTRY PS,et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis:A randomized,phase 2 trial[J]. Hepatology,2018,67(2):549-559.

[22] HARRISON SA,WONG VW,OKANOUE T,et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH:Results from randomized phase III STELLAR trials[J]. J Hepatol,2020,73(1):26-39.

[23] SHIFFMAN M,FREILICH B,VUPPALANCHI R,et al. Randomised clinical trial:Emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther,2019,49(1):64-73.

[24] HARRISON SA,GOODMAN Z,JABBAR A,et al. A randomized,placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis[J]. J Hepatol,2020,72(5):816-827.

[25] FRIEDMAN SL,RATZIU V,HARRISON SA,et al. A randomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology,2018,67(5):1754-1767.

[26] HARRISON SA,ABDELMALEK MF,CALDWELL S,et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis[J]. Gastroenterology,2018,155(4):1140-1153.

[27] HARRISON SA,ROSSI SJ,PAREDES AH,et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis[J]. Hepatology,2020,71(4):1198-1212.

[28] SANYAL A,CHARLES ED,NEUSCHWANDER-TETRI BA,et al.Pegbelfermin(BMS-986036),a PEGylated fibroblast growth factor 21 analogue,in patients with non-alcoholic steatohepatitis:A randomised,double-blind,placebo-controlled,phase 2a trial[J]. Lancet,2019,392(10165):2705-2717.

[29] LOOMBA R,KAYALI Z,NOUREDDIN M,et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2018,155(5):1463-1473. e6.

[30] ESLAM M,NEWSOME PN,SARIN SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020,73(1):202-209.

施引文献

资源附件(0)

访问统计